| AGENUS INC - Fundamental Profile|| |
| Company Information |
| Ticker Symbol:
| Contact Info:
|| 162 FIFTH AVENUE SUITE 900
NEW YORK NY 10010
|| Garo H. Armen
|SIC: 2836, Medical - Biomedical
|| Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company's product line includes Oncophage vaccine, a patient-specific therapeutic cancer vaccine. The Company is also developing Prophage, patient-specific therapeutic cancer vaccine; QS-21, vaccine adjuvant; and HerpV, a polyvalent off-the-shelf therapeutic heat shock protein-based vaccine for treatment of genital herpes which are all in the clinical testing stages. Agenus Inc. is headquartered in Lexington, Massachusetts.
| Share Information |
| Market Value, $K:
|| Shares Outstanding, K:
| % Held by Insiders:
|| % Institutional Shareholders:
| Last Quarter Sales, $M:
|| Last Quarter Net Income, $M:
| Last Quarter EPS:
|| P/E Ratio:
| Annual EPS, $:
|| Most Recent Earnings, $:
| Annual Dividend Rate, $:
|| Most Recent Dividend:
| Annual Dividend Yield, %:
|| Most Recent Split:
|| 1-6 on 10/03/11
Fundamental information provided by Zacks Investment Research, Inc.
Zacks does not represent, warrant,
or guarantee completeness, accuracy or timeliness of its data, and shall have no liability of any kind whatsoever
to any party on account of any incompleteness of, inaccuracies in or untimeliness of the Zacks content provided
hereunder, or for any delay in reporting such data. Zacks expressly disclaims all warranties of fitness of the
Zacks content or computations and analyses thereof for a particular purpose or use.|
All Equities and Futures data is delayed according to exchange rules.
NYSE, AMEX and Nasdaq 15 minutes. Futures exchanges 10 minutes.